< Back to all Team Members

Michael G. Martin, MD

Medical Oncologist

Education:

University of Memphis

Bachelor of Science, summa cum laude

Biology major, Chemistry minor

January 1996 – August 1999

  • Studied Abroad in Australia and New Zealand, Summer of 1997
  • Studied Abroad at the University of Helsinki, Finland, Fall of 1998

 

University of Tennessee, College of Medicine

Medical Doctorate with Highest Honors, August 1999 – May 2003

  • Rotated in Recife, Brazil as a part of the Jude Professional Oncology Experience program, Summer 2000

 

Duke University Medical Center

Internship and Residency in Internal Medicine

June 2003 – June 2006

 

Washington University in St. Louis School of Medicine

Fellow in Medical Oncology

July 2006 – June 2009

  • Post-doctoral fellow in lab of Matthew J Walter, MD, July 2007 – June 2009

 

Honors and Awards:

(1999) Summa cum laude, University of Memphis

(2003) Outstanding Medical Student Award – Neurology

(2003) Alpha Omega Alpha

(2003) Graduated University of Tennessee Medical School with Highest Honors

(2003) Faculty Medal – For Highest Academic Achievement (GPA 4.00) (University of Tennessee HSC)

(2008) Finalist for American Society of Hematology Fellow Research Training Award

(2012) Faculty of the Year – The West Clinic/University of Tennessee Division of Hematology/Oncology

(2014) Outstanding Attending Award – The University of Tennessee College of Medicine

(2014-15) Student Government Association Executive Council Excellence in Teaching Award for Outstanding Teaching and Genuine Concern for Students, The University of Tennessee HSC College of Medicine

(2015-16) The Marion Dugdale Outstanding Faculty Award – The West Cancer Center/ University of Tennessee Division of Hematology/Oncology

(2018) Fulbright Scholar in Medical Oncology, Abuja and Lagos, Nigeria with Project PinkBlue and National Hospital Abuja and Lagos University Teaching Hospital, https://ng.usembassy.gov/u-s-embassy-supports-training-of-44-nigerian-medical-oncologists

 

Mentored Awards:

(2014) 15th Annual Fellows Travel Award to the 24th Annual Mayo Clinic Hematology/Oncology Review (M Pandey)

(2015) Alpha Omega Alpha/University of Tennessee College of Medicine Resident Research Award (PE Prouet)

(2015) 16th Annual Fellows Travel Award to the 25th Annual Mayo Clinic Hematology/Oncology Review (E Wiedower)

(2015) Medical Student Achievement in Research Award University of Tennessee College of Medicine (A Hahn)

(2015) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (O Jamy)

(2015) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (E Wiedower) (2015) American Society of Hematology Annual Meeting Abstract Achievement Award (E Wiedower)

(2016) 17th Annual Fellows Travel Award to the 26th Annual Mayo Clinic Hematology/Oncology Review (M Chi)

(2016) 17th Annual Fellows Travel Award to the 26th Annual Mayo Clinic Hematology/Oncology Review (G Yaghmour)

(2016) 17th Annual Fellows Travel Award to the 26th Annual Mayo Clinic Hematology/Oncology Review (S Nasir)

(2016) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (M Crawley)

(2016) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (K Patel)

(2016) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (M Mirza)

(2016) American Society of Hematology Hematologic Malignancy Abstract Achievement Award (N Vontela)

(2016-19) American Society of Clinical Oncology Cancer Interest Group for Medical Students Award (E Vick)

(2016) American Society of Hematology Annual Meeting Abstract Achievement Award (D Patel)

(2017) Alpha Omega Alpha/University of Tennessee College of Medicine Resident Research Award – Second Place (tie) (K Patel)

(2017) Alpha Omega Alpha/University of Tennessee College of Medicine Resident Research Award – Second Place (tie) (U Giri)

(2017) Presenter at ASCO-Sponsored Cancer Interest Group Abstract Forum (E Vick)

(2017) Presenter at ASCO-Sponsored Cancer Interest Group Abstract Forum (J Malpartida)

(2017) 18th Annual Fellows Travel Award to the 27th Annual Mayo Clinic Hematology/Oncology Review (S Nasir)

(2017) 18th Annual Fellows Travel Award to the 27th Annual Mayo Clinic Hematology/Oncology Review (K Byrd)

(2017) 18th Annual Fellows Travel Award to the 27th Annual Mayo Clinic Hematology/Oncology Review (PE Prouet)

(2017) 18th Annual Fellows Travel Award to the 27th Annual Mayo Clinic Hematology/Oncology Review (F Hare)

(2017) 18th Annual Fellows Travel Award to the 27th Annual Mayo Clinic Hematology/Oncology Review (M Mirza)

(2017) American Society of Hematology Annual Meeting Abstract Achievement Award (E Vick)

(2017) American Society of Hematology Annual Meeting Abstract Achievement Award (U Giri)

(2018) Alpha Omega Alpha/University of Tennessee College of Medicine Resident Research Award – First Place (U Giri)

(2018) 19th Annual Fellows Travel Award to the 28th Annual Mayo Clinic Hematology/Oncology Review (J Porter)

(2018) 19th Annual Fellows Travel Award to the 28th Annual Mayo Clinic Hematology/Oncology Review (M Stein)

(2018) 19th Annual Fellows Travel Award to the 28th Annual Mayo Clinic Hematology/Oncology Review (A Altahan)

 

Board Certification:

Internal Medicine (2006)

Medical Oncology (2010)

 

Medical Licenses:

Missouri (2008)

Tennessee (2009 – active)

Mississippi (2009 – active)

 

Professional Societies and Organizations:

Member of the American Society of Hematology (2006 to present)

Member of the American Society of Clinical Oncology (2006 to present)

 

Hospital and Clinical Appointments:

Methodist Olive Branch (November 2013  – present)

Health South Rehab of Memphis (December 2009 – present)

Methodist Extended Care (October 2009 – present)

Fayette County Hospital (August 2009 – present)

St. Francis Bartlett (July 2009 – present)

St. Francis Memphis (July 2009 – present)

Baptist Metro (July 2009 – present)

Methodist Healthcare Memphis Hospitals (August 2009 – present)

 

Practice and Professional Experience:

The West Cancer Center, Medical Oncologist, Memphis, TN (August 2009 – present)

Editor-in-Chief World Journal of Oncology, Elmer Press (February 2018 – present) (http://www.wjon.org/index.php/wjon/pages/view/editorialTeam)

 

Teaching Experience:

Assistant Professor of Medicine, University of Tennessee Health Science Center, Memphis, TN (May 2012 – June 2015)

Associate Professor of Medicine, University of Tennessee Health Science Center, Memphis, TN (July 2015 – present)

 

Invited Lectures Outside of The University of Tennessee:

  1. University of Florida Cancer Center Visiting Professor Grand Rounds “Age and Hematologic Malignancies” (November 2016)
  2. Lectures associated with Fulbright Specialist Program in Abuja and Lagos, Nigeria (August 2018) https://www.premiumtimesng.com/health/280156-u-s-trains-44-nigerian-oncologists.html
  3. Immunotherapy in Oncology (African University of Science and Technology (AUST))
  4. Genetics of Oncology (AUST)
  5. Targeted Therapy in Oncology (AUST)
  6. Hodgkin’s Lymphoma (AUST)
  7. Diffuse Large B-cell Lymphoma (AUST)
  8. Lung Cancer, both Small Cell and Non-small Cell (AUST)
  9. Pancreatic Cancer (AUST)
  10. Colon Cancer (AUST)
  11. Gastro-esophageal Cancer (AUST)
  12. Advances in Cancer Genetics and Immunotherapy (Lagos University Teaching Hospital)

 

Invited Lectures at The University of Tennessee/West Cancer Center:

  1. NSCLC “ University of Tennessee Internal Medicine Morning Report (October 2012)
  2. Hodgkin’s Disease University of Tennessee Hematology and Oncology Fellowship lecture series (January 2013)
  3. “Acute Myeloid Leukemia Diagnosis, Prognosis and Supportive Care” University of Tennessee Hematology and Oncology Fellowship lecture series (January 2013)
  4. “GI Cancers” University of Tennessee Internal Medicine educational lecture series (January 2013)
  5. “Lung Cancer” University of Tennessee Internal Medicine educational lecture series (January 2013)
  6. “Medical Oncology for Surgeons” University of Tennessee Surgery monthly conference (January 2013)
  7. “What’s new in AML” West Clinic/University of Tennessee Medical Oncology meeting (March 2013)
  8. “Avoiding Physician Burnout” Serving the Underserved curriculum, the Church Health Center (March 2013)
  9. “Liquid Oncology Case presentations” University of Tennessee First Year Medical Student Pathophysiology Lecture (March 2013)
  10. “Acute Myeloid Leukemia Treatment” University of Tennessee Hematology and Oncology Fellowship lecture series (April 2013)
  11. “Exotic Liquid Oncology” University of Tennessee Hematology and Oncology Fellowship lecture series (May 2013)
  12. “Primary CNS Tumors” University of Tennessee College of Pharmacy core lecture series (August 2013)
  13. Hodgkin’s Disease Update University of Tennessee Hematology and Oncology Fellowship lecture series (August 2013)
  14. “Advances in Lung Cancer” University of Tennessee Internal Medicine educational lecture series (January 2014)
  15. “Advances in GI Cancers” University of Tennessee Internal Medicine educational lecture series (January 2014)
  16. 16. “Leukemia” University of Tennessee Internal Medicine educational lecture series (January 2014)
  17. “Acute Myeloid Leukemia 101” University of Tennessee Hematology and Oncology Fellowship lecture series (January 2014)
  18. “How to become an oncologist” University of Tennessee Health Science Center lecture to M1 and M2’s (February 2014)
  19. “How to avoid physician burnout” Women in Medical Sciences (WIMS), of Tennessee Health Science Center (February 2014)
  20. “Ma’am we have a problem, DLBCL” University of Tennessee Hematology and Oncology Fellowship lecture series (September 2014)
  21. “I don’t want any chemo! Hodgkin’s disease” University of Tennessee Hematology and Oncology Fellowship lecture series (September 2014)
  22. “Four cases of lung cancer and down the rabbit hole” University of Tennessee Internal Medicine educational lecture series (January 2015)
  23. “Three GI cases and would you take adjuvant gemcitabine or FOLFIRINOX?” University of Tennessee Internal Medicine educational lecture series (January 2015)
  24. “Leukemia and through the looking glass” University of Tennessee Internal Medicine educational lecture series (January 2015)
  25. “Acute Myeloid Leukemia cases” University of Tennessee Hematology and Oncology Fellowship lecture series (February 2015)
  26. “DLBCL” University of Tennessee Hematology and Oncology Fellowship lecture series (September 2015)
  27. “Lung Cancer and Immunotherapy” University of Tennessee Internal Medicine educational lecture series (November 2015)
  28. “Colorectal Cancer” University of Tennessee Internal Medicine educational lecture series (November 2015)
  29. “The Acute Leukemias” University of Tennessee Internal Medicine educational lecture series (December 2015)
  30. “Hodgkin Lymphoma” University of Tennessee Hematology and Oncology Fellowship lecture series (February 2016)
  31. “Diagnosis and Prognosis of Acute Myeloid Leukemia” University of Tennessee Hematology and Oncology Fellowship lecture series (March 2016)
  32. “Treatment of Acute Myeloid Leukemia” University of Tennessee Hematology and Oncology Fellowship lecture series (April 2016)
  33. “Avoiding Physician Burnout” Serving the Underserved curriculum, the Church Health Center (April 2016)
  34. “The Aggressive Lymphomas with a focus on ACLC and DLBCL” University of Tennessee Hematology and Oncology Fellowship lecture series (September 2016)
  35. “Chronic Lymphocytic Leukemia Update” West Cancer Center Medical Oncology Meeting presentation (September 2016)
  36. “NHL update” West Cancer Center Medical Oncology Meeting presentation (October 2016)
  37. “Hodgkin’s Lymphoma – Focus on Response Adapted Therapy” University of Tennessee Hematology and Oncology Fellowship lecture series (November 2016)
  38. “Innovations in Medical Oncology” Hematology and Oncology Student Interest Group Noon conference (December 2016)
  39. “Management of Acute Myeloid Leukemia” University of Tennessee Hematology and Oncology Fellowship lecture series (March 2017)
  40. “PCNSL and Database Research” University of Tennessee Hematology and Oncology Fellowship lecture series (April 2017)
  41. “Cases in Medical Oncology” University of Tennessee Hematology and Oncology Fellowship lecture series (May 2017)
  42. “Nodular Lymphocyte Predominant Hodgkin Disease” University of Tennessee Hematology and Oncology Fellowship lecture series (September 2017)
  43. “Four new drugs from AML and other updates” University of Tennessee Hematology and Oncology Fellowship lecture series (September 2017)
  44. “Aggressive NHL” University of Tennessee Hematology and Oncology Fellowship lecture series (February 2018)
  45. “Acute Lymphoblastic Leukemia” University of Tennessee Hematology and Oncology Fellowship lecture series (April 2018)
  46. “Evolution of Lung Cancer” University of Tennessee Hematology Oncology Interest Group Noon Lecture in conjunction with ASCO student interest group award (September 2018)

 

Peer Reviewed Manuscripts:

  1. Deferasirox versus deferoxamine.

Martin MG, Arcasoy MO.

Blood. 2006 Jul 15;108(2):774-5; author reply 775-6. No abstract available. PMID: 16822908

 

  1. Social consequence of disease in the American South, 1900-World War II.

Martin MG, Humphreys ME.

South Med J. 2006 Aug;99(8):862-4. Review. PMID: 16929881

 

  1. Small cell lung cancer presenting as a paraneoplastic syndrome characterized by recurrent episodic hypotension and bradycardia: case report.

Martin MG, Ardati AK, Dunlay SM, Abernethy AP, Blazing MA.

Chest. 2007 Jan;131(1):290-3. PMID: 17218589

 

  1. Encephalopathy with myoclonic jerks resulting from ceftazidime therapy: an under-recognizedpotential side-effect when treating febrile neutropenia.

Martin MG.

Leuk Lymphoma. 2007 Feb;48(2):413-4. No abstract available. PMID: 17325906

 

  1. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah’s Witness.

Martin MG, Whitlatch NL, Shah B, Arepally GM.

Am J Hematol. 2007 Jul;82(7):679-81. PMID: 17266059

 

  1. Gene expression profiling in diffuse large B-cell lymphoma.

Morgensztern D, Martin MG, Lossos IS.

Leuk Lymphoma. 2007 Apr;48(4):669-82. Review. PMID: 17454624

 

  1. Second-line therapy for esophageal cancer.

Martin MG, Govindan R, Morgensztern D.

Expert Rev Anticancer Ther. 2007 Jun;7(6):871-6. Review. PMID: 17555397

 

  1. Whitlatch NL, Martin MG, Shah BD, Arepally GM. Response to Boctor and Smith. Am J Hematol. 2008; 83(3): 256. [Epub ahead of print] 2007 Oct 4.

 

  1. Induction therapy for elderly patients with acute myeloid leukemia.

Martin MG, Abboud CN.

Blood Rev. 2008 Nov;22(6):311-20. doi: 10.1016/j.blre.2008.04.004. Epub 2008 Jun 9. PMID: 18539373

 

  1. Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.

Martin MG, Dipersio JF, Uy GL.

Leuk Lymphoma. 2009 Jan;50(1):14-23. doi: 10.1080/10428190802517765. Review. PMID: 19117213

 

  1. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.

Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R.

Bone Marrow Transplant. 2009 Jul;44(1):13-7. doi: 10.1038/bmt.2008.423. Epub 2009 Jan 12. PMID: 19139740

 

  1. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.

Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL, Walshauser MA, Martin MG, Kasai Y, Walter MJ.

PLoS One. 2009;4(2):e4583. doi: 10.1371/journal.pone.0004583. Epub 2009 Feb 25. PMID: 19240791

 

  1. Martin MG, DiPersio JD, Uy G. Importance of durable response in CML. Oncol Rev. 2009; 3(1):59-70.

 

  1. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma:a single-center case series and review of the literature.

Martin MG, Vij R.

Clin Lymphoma Myeloma. 2009 Aug;9(4):320-3. doi: 10.3816/CLM.2009.n.063. Review. PMID: 19717384

 

  1. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience.

Martin MG, Welch JS, Augustin K, Hladnik L, DiPersio JF, Abboud CN.

Clin Lymphoma Myeloma. 2009 Aug;9(4):298-301. doi: 10.3816/CLM.2009.n.058. PMID:19717379

 

  1. Dicer and outcomes in patients with acute myeloid leukemia (AML).

Martin MG, Payton JE, Link DC.

Leuk Res. 2009 Aug;33(8):e127. doi: 10.1016/j.leukres.2009.02.003. Epub 2009 Mar 10. No abstract available. PMID: 19278725

 

  1. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study.

Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ.

Breast Cancer Res Treat. 2009 Dec;118(3):593-8. doi: 10.1007/s10549-009-0376-3. Epub 2009 Mar 26. PMID: 19322652

 

  1. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.

Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, Dipersio JF, Vij R.

Am J Hematol. 2009 Sep;84(9):560-4. doi: 10.1002/ajh.21482. PMID: 19650118

 

  1. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.

Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, Dipersio JF, Vij R.

Am J Hematol. 2009 Nov;84(11):733-7. doi: 10.1002/ajh.21545. PMID: 19806665

 

  1. Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice.

Martin MG, Welch JS, Uy GL, Fehniger TA, Kulkarni S, Duncavage EJ, Walter MJ.

Leukemia. 2010 Sep;24(9):1662-4. doi: 10.1038/leu.2010.156. Epub 2010 Jul 29. No abstract available. PMID: 20668474

 

  1. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma.

Cheuk DK, Billups CA, Martin MG, Roland CR, Ribeiro RC, Krasin MJ, Rodriguez-Galindo C.

Cancer. 2011 Jan 1;117(1):197-206. doi: 10.1002/cncr.25376. Epub 2010 Aug 24. PMID:20737561

 

  1. Rectal cancer.

Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM.

J Natl Compr Canc Netw. 2012 Dec 1;10(12):1528-64. PMID:23221790

 

  1. Acute myeloid leukemia, version 2.2013.

O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1047-55. PMID:24029121

 

  1. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.

Jacoby MA, Martin MG, Uy GL, Westervelt P, Dipersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN.

Am J Hematol. 2014 May;89(5):487-92. doi: 10.1002/ajh.23663. Epub 2014 Mar 3. PMID:24415560

 

  1. The evolving role of surgery for gastric lymphoma: from curative resection to surgical management of complications.

Paulus EM, Fleming MD, Hendrix AA, Deneve JL, Dickson PV, Mathew A, Martin MG, Munene G.

Am Surg. 2014 Nov;80(11):E322-4. No abstract available. PMID: 25347493

 

  1. Primary Angiosarcoma of the Breast: A Case Report and Review of Literature.

Pandey M, Martin MG.

World J Oncol. 2014 Jun;5(3):144-148. doi: 10.14740/wjon809w. Epub 2014 Jun 25. PMID: 29147394

 

  1. Seasonal variation in the presentation of thyroid cancer in the USA: an analysis of the Surveillance, Epidemiology and End Results Registry.

Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, Martin MG.

Cancer Causes Control. 2014 Nov;25(11):1583-5. doi: 10.1007/s10552-014-0453-8. Epub 2014 Aug 19. No abstract available. PMID: 25135614

 

  1. Seasonal and regional variation of thrombotic thrombocytopenic purpura in the United States: insights from the Nationwide Inpatient Sample.

Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, Martin MG.

Am J Hematol. 2015 Jan;90(1):E24. doi: 10.1002/ajh.23853. Epub 2014 Oct 18. No abstract available. PMID: 25229615

 

  1. Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia.

Giri S, Pathak R, Prouet P, Li B, Martin MG.

Blood. 2014 Dec 11;124(25):3833-4. doi: 10.1182/blood-2014-09-603415. No abstract available. PMID: 25498456

 

  1. Incidence trend of esophageal squamous cell carcinoma: an analysis of Surveillance Epidemiology, and End Results (SEER) database.

Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, Martin MG.

Cancer Causes Control. 2015 Jan;26(1):159-61. doi: 10.1007/s10552-014-0485-0. Epub 2014 Nov 7. No abstract available. PMID: 25376829

 

  1. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States.

Pathak R, Giri S, Aryal MR, Karmacharya P, Bhatt VR, Martin MG.

Support Care Cancer. 2015 Mar;23(3):615-7. doi: 10.1007/s00520-014-2553-0. Epub 2015 Jan 4. PMID: 25556610

 

  1. Lack of “weekend effect” on mortality for pulmonary embolism admissions in 2011: data fronationwide inpatient sample.

Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, Martin MG.

Int J Cardiol. 2015 Feb 1;180:151-3. doi: 10.1016/j.ijcard.2014.11.201. Epub 2014 Nov 26. No abstract available. PMID: 25438238

 

  1. Influence of insurance and marital status on outcomes of adolescents and young adults with acute lymphoblastic leukemia.

Fintel AE, Jamy O, Martin MG.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):364-7. doi: 10.1016/j.clml.2014.12.006. Epub 2014 Dec 12. PMID: 25592548

 

  1. Ibrutinib has some activity in Richter’s syndrome.

Giri S, Hahn A, Yaghmour G, Martin MG.

Blood Cancer J. 2015 Jan 30;5:e277. doi: 10.1038/bcj.2014.98. No abstract available. PMID: 25635530

 

  1. Grade and Prognosis in Localized Primary Angiosarcoma.

Pandey M, Sutton GR, Giri S, Martin MG.

Clin Breast Cancer. 2015 Aug;15(4):266-9. doi: 10.1016/j.clbc.2014.12.009. Epub 2015 Jan 3. PMID: 25659906

 

  1. Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study.

Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, Martin MG.

Blood. 2015 May 21;125(21):3359-60. doi: 10.1182/blood-2015-01-625764. No abstract available. PMID: 25999448

 

  1. Early mortality in acute myeloid leukemia.

Hahn A, Giri S, Yaghmour G, Martin MG.

Leuk Res. 2015 May;39(5):505-9. doi: 10.1016/j.leukres.2015.02.003. Epub 2015 Feb 9. PMID: 25726083

 

  1. Meta-analysis of 21- versus 22-G aspiration needle during endobronchial ultrasound-guided transbronchial needle aspiration.

Giri S, Pathak R, Yarlagadda V, Karmacharya P, Aryal MR, Martin MG.

J Bronchology Interv Pulmonol. 2015 Apr;22(2):107-13. doi: 10.1097/LBR.0000000000000159. PMID: 25887005

 

  1. Population-based Analysis of the Clinical Features of Primary Small Cell Carcinoma of the Ovary.

Jamy O, Yaghmour G, Hare F, Martin MG.

Anticancer Res. 2015 May;35(5):3091-5. PMID: 25964600

 

  1. Second primary malignancies in Waldenstrom’s macroglobulinemia: a US population-based study.

Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, Martin MG.

Cancer Causes Control. 2015 Apr;26(4):645-7. doi: 10.1007/s10552-015-0545-0. Epub 2015 Mar 3. No abstract available. PMID: 25732345

 

  1. A population-based analysis of outcomes for small cell carcinoma of the breast by tumor stage and the use of radiation therapy.

Hare F, Giri S, Patel JK, Hahn A, Martin MG.

Springerplus. 2015 Mar 21;4:138. doi: 10.1186/s40064-015-0913-y. eCollection 2015. PMID: 25853028

 

  1. Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis.

Hahn AW, Giri S, Patel D, Sluder H, Vanderwalde A, Martin MG.

J Natl Compr Canc Netw. 2015 Oct;13(10):1181-5. PMID: 26483058

 

  1. Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database.

Giri S, Pathak R, Martin MG, Bhatt VR.

Leuk Lymphoma. 2015 Sep 4:1-7. [Epub ahead of print] PMID: 26084205

 

  1. How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia.

Hahn AW, Jamy O, Nunnery S, Yaghmour G, Giri S, Pathak R, Martin MG.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):646-54. doi: 10.1016/j.clml.2015.07.646. Epub 2015 Aug 5. Review. PMID: 26386907

 

  1. Rapid evolution of intracranial Myeloid Sarcoma in Four Weeks.

Prouet PE, Martin MG. Blood 2015 126:1256; doi: https://doi.org/10.1182/blood-2015-05-647388

PMID: 26569014

 

  1. Acute megakaryocytic leukemia: What have we learned.

Hahn AW, Li B, Prouet P, Giri S, Pathak R, Martin MG.

Blood Rev. 2016 Jan;30(1):49-53. doi: 10.1016/j.blre.2015.07.005. Epub 2015 Jul 18. Review. PMID: 26228843

 

  1. Sister Mary Joseph’s nodule in a patient with metastatic small cell lung cancer.

Ghimire S, Giri S, Pathak R, Martin MG.

J Community Hosp Intern Med Perspect. 2015 Jun 15;5(3):27388. doi: 10.3402/jchimp.v5.27388. eCollection 2015. PMID: 26091656

 

  1. Comparative Survival of Patients With Anal Adenocarcinoma, Squamous Cell Carcinoma of the Anus, and Rectal Adenocarcinoma.

Franklin RA, Giri S, Valasareddy P, Lands LT, Martin MG.

Clin Colorectal Cancer. 2016 Mar;15(1):47-53. doi: 10.1016/j.clcc.2015.07.007. Epub 2015 Aug 1. PMID: 26362848

 

  1. Incidence of breast cancer among female survivors of Hodgkin lymphoma: a US-population-based trend analysis from 1973 to 2011.

Giri S, Pathak R, Martin MG, Bhatt VR.

Blood. 2015 Oct 8;126(15):1861-3. doi: 10.1182/blood-2015-05-647412. Epub 2015 Aug 17. No abstract available.

PMID: 26282539

 

  1. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.

Wiedower E, Jamy O, Martin MG.

Anticancer Res. 2015 Nov;35(11):6287-90.

PMID: 26504064

 

  1. Seasonal variation of immune thrombocytopenic purpura related hospitalizations among adults in the USA: analysis of the nationwide inpatient sample database.

Giri S, Pathak R, Aryal MR, Karmacharya P, Bhatt VR, Martin MG.

Ther Adv Hematol. 2015 Aug;6(4):217-8. doi: 10.1177/2040620715582146. No abstract available.

PMID: 26288716 Free PMC Article

 

  1. Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis.

Giri S, Chi M, Johnson B, McCormick D, Jamy O, Bhatt VR, Martin MG.

Leuk Res. 2015 Dec;39(12):1342-6. doi: 10.1016/j.leukres.2015.09.011. Epub 2015 Sep 12.

PMID: 26427729

 

  1. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database.

Giri S, Pathak R, Martin MG, Bhatt VR.

Ther Adv Hematol. 2015 Dec;6(6):308-12. doi: 10.1177/2040620715607416. No abstract available.

PMID: 26622999 Free PMC Article

 

  1. Precision medicine: lessons learned from the SHIVA trial.

Hahn AW, Martin MG.

Lancet Oncol. 2015 Dec;16(16):e580-1. doi: 10.1016/S1470-2045(15)00458-1. No abstract available.

PMID: 26678198

 

  1. Comorbidities Drive Outcomes for Both Malignancy-Associated and Non-Malignancy-Associated Hemophagocytic Syndrome.

Johnson B, Giri S, Nunnery SE, Wiedower E, Jamy O, Yaghmour G, Chandler JC, Martin MG.

Clin Lymphoma Myeloma Leuk. 2016 Jan 12. pii: S2152-2650(16)00021-5. doi: 10.1016/j.clml.2016.01.002. [Epub ahead of print]

PMID: 26837475

 

  1. Treatment Disparities Faced by Undocumented Workers From Low- and Middle-Income Countries in the United States With Hematologic Malignancies.

Nunnery SE, Fintel AE, Jackson WC, Chandler JC, Ugwueke MO, Martin MG.

J Natl Compr Canc Netw. 2016 Apr;14(4):483-6. No abstract available.

PMID: 27059195

 

  1. Under-recognition of hemophagocytic syndrome in United States’ rural, non-teaching hospitals.

Jamy O, Nunnery S, Giri S, Wiedower E, Johnson B, Yaghmour G, Martin MG.

Leuk Lymphoma. 2016 Apr 18:1-3. [Epub ahead of print] No abstract available.

PMID: 27087428

 

  1. Hahn A, Martin MG. RE: Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. http://www.bloodjournal.org/content/127/14/1752.e-letters#

 

  1. Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.

McCullar B, Pandey M, Yaghmour G, Hare F, Patel K, Stein M, Feldman R, Chandler JC, Martin MG.

Breast Cancer Res Treat. 2016 Jun 21. [Epub ahead of print]

PMID: 27329168

 

  1. Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract.

Hahn AW, Giri S, Pathak R, Bhatt VR, Martin MG.

Anticancer Res. 2016 Aug;36(8):4051-5.

PMID: 27466512

 

  1. Hospital volume and acute myeloid leukemia mortality in Medicare beneficiaries aged 65 and older.

Thompson MP, Waters TM, Kaplan EK, McKillop CN, Martin MG.

Blood. 2016 Jun 29. pii: blood-2016-05-716662. [Epub ahead of print] No abstract available.

PMID: 27357700

 

  1. Role of Genomic Instability in Immunotherapy with Checkpoint Inhibitors.

Yaghmour G, Pandey M, Ireland C, Patel K, Nunnery S, Powell D, Baum S, Wiedower E, Schwartzberg LS, Martin MG.

Anticancer Res. 2016 Aug;36(8):4033-8.

PMID: 27466509

 

  1. Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic lymphocytic leukemia.

Wiedower E, Hare F, Arthur A, Chandler J, Martin MG.

Ther Adv Hematol. 2016 Aug;7(4):231-2. doi: 10.1177/2040620716648563. Epub 2016 May 17. No abstract available.

PMID: 27493713

 

  1. Genomic alterations in neuroendocrine cancers of the ovary.

Yaghmour G, Prouet P, Wiedower E, Jamy OH, Feldman R, Chandler JC, Pandey M, Martin MG.

J Ovarian Res. 2016 Aug 26;9(1):52. doi: 10.1186/s13048-016-0259-2.

PMID: 27566252

 

  1. Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia.

Nasir SS, Giri S, Nunnery S, Martin MG.

Clin Lymphoma Myeloma Leuk. 2016 Sep 17. pii: S2152-2650(16)30567-5. doi: 10.1016/j.clml.2016.09.011. [Epub ahead of print]

PMID: 27836483

 

  1. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum.

Sandlund JT, Martin MG.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):589-597.

PMID: 27913533

 

  1. Genetic analysis of B-cell lymphomas associated with hemophagocytic lymphohistiocytosis.

Patel K, Lee SS, Valasareddy P, Vontela NR, Prouet P, Martin MG.

Blood Adv. 2016 Dec 14;1(3):205-207. doi: 10.1182/bloodadvances.2016002006. eCollection 2016 Dec 27. No abstract available. PMID: 29296936

 

  1. Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality.

Prouet P, Giri S, Wiedower E, Fintel A, Yaghmour G, Lamb EP, Deneve J, Fleming M, Dickson P, Chandler JC, Martin MG.

Anticancer Res. 2017 Feb;37(2):813-817.

PMID: 28179335

 

  1. Sweet’s syndrome associated with clonal hematopoiesis of indeterminate potential responsive to 5-azacitidine.

Yaghmour G, Wiedower E, Yaghmour B, Nunnery S, Duncavage E, Martin MG.

Ther Adv Hematol. 2017 Feb;8(2):91-95. doi: 10.1177/2040620716680330. Review.

PMID: 28203345

 

  1. Well-Differentiated, Non-Functional, Non-Ampullary Duodenal Neuroendocrine Tumors: Toward Defining Evaluation and Management.

Weatherall T, Denbo J, Sharpe J, Martin M, O’Brien T, Gupta R, Groshart K, Behrman S, Dickson P.

World J Surg. 2017 Mar;41(3):844-850. doi: 10.1007/s00268-016-3770-0.

PMID: 27743074

 

  1. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2017 Mar;15(3):293-311.

PMID: 28275031

 

  1. 9p24 abnormalities in hematologic malignancies with a focus on diffuse large B-cell lymphoma.

Patel DA, Hahn AW, Martin MG.

Med Oncol. 2017 May;34(5):95. doi: 10.1007/s12032-017-0957-7. Epub 2017 Apr 13. No abstract available.

PMID: 28409436

 

  1. Survival outcomes in the very elderly with DLBCL prior to and after the introduction of rituximab: a US population-based study.

Giri U, Martin MG.

Blood Adv. 2017 Apr 6;1(10):615-618. doi: 10.1182/bloodadvances.2016002675. eCollection 2017 Apr 11. No abstract available. PMID: 29296703

 

  1. Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing.

Stein MK, Morris L, Sullivan JL, Fenton M, VanderWalde A, Schwartzberg LS, Martin MG.

Med Oncol. 2017 Jul;34(7):126. doi: 10.1007/s12032-017-0985-3. Epub 2017 Jun 1.

PMID: 28573640

 

  1. Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy.

Vick EJ, Patel K, Prouet P, Martin MG.

Blood Adv. 2017 May 9;1(12):779-791. doi: 10.1182/bloodadvances.2017005561. eCollection 2017 May 9. Review. PMID: 29296722

 

  1. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N. J Natl Compr Canc Netw. 2017 Jul;15(7):926-957. doi: 10.6004/jnccn.2017.0116.

PMID: 28687581

 

  1. Navigational bronchoscopy-guided dye marking to assist resection of a small lung nodule.

Sullivan JL, Martin MG, Weksler B.

J Vis Surg. 2017 Sep 30;3:131. doi: 10.21037/jovs.2017.08.08. eCollection 2017.

PMID: 29078691

 

  1. Role Of Early Evaluation For Clonal Heterogeneity In Acute Myeloid Leukemia.

Stein M, Nasir SS, Palazola B, Crawley M, Martin MG.

International Journal of Hematology and Therapy.  https://doi.org/10.15436/2381-1404.17.020

 

  1. Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer.

McCullar B, Alloway T, Martin M.

J Thorac Dis. 2017 Jun;9(6):E540-E542. doi: 10.21037/jtd.2017.05.32.

PMID:28740692

 

  1. Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma.

Byrd KP, Vontela NR, McCullar B, Martin MG.

Anticancer Res. 2017 Dec;37(12):6839-6843.

PMID:29187463

 

  1. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.

Ferguson MD, Dong L, Wan J, Deneve JL, Dickson PV, Behrman SW, Shibata D, Martin MG, Glazer ES.

J Gastrointest Cancer. 2018 Feb 10. doi: 10.1007/s12029-018-0073-8. [Epub ahead of print] PMID: 29427136

 

  1. Adjuvant Therapy in Resected Melanoma.

Thomson N, Doerr R, Martin MG.

N Engl J Med. 2018 Feb 15;378(7):678-9. doi: 10.1056/NEJMc1716071. No abstract available. PMID: 29446285

 

  1. Ampullary adenocarcinoma: Defining predictors of survival and the impact of adjuvant therapy following surgical resection for stage I disease.

Stiles ZE, Behrman SW, Deneve JL, Glazer ES, Dong L, Wan JY, Martin MG, Dickson PV.

J Surg Oncol. 2018 Mar 8. doi: 10.1002/jso.25021. [Epub ahead of print] PMID: 29518820

 

  1. Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer.

Guo S, Martin MG, Tian C, Cui J, Wang L, Wu S, Gu W.

J Cancer. 2018 Mar 22;9(7):1287-1300. doi: 10.7150/jca.22020. eCollection 2018. Review. PMID: 29675110

 

  1. Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy.

Guerrero WL, Munene G, Dickson PV, Darby D, Davidoff AM, Martin MG, Glazer ES, Shibata D, Deneve JL.

J Gastrointest Oncol. 2018 Apr;9(2):338-347. doi: 10.21037/jgo.2018.01.02. PMID: 29755773

 

  1. Impact of Provider Volume on Outcomes of Patients With Hodgkin Lymphoma.

Ireland C, Wiedower E, Mirza M, Crawley M, Tran A, Yaghmour G, Martin MG.

World J Oncol. 2018 Apr;9(2):46-49. doi: 10.14740/wjon1093w. Epub 2018 May 1. PMID: 29760832

 

  1. Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib.

Stein MK, Karri S, Reynolds J, Owsley J, Wise A, Martin MG, Zare F.

World J Oncol. 2018 Apr;9(2):62-65. doi: 10.14740/wjon1099w. Epub 2018 May 1. PMID: 29760835

 

  1. ConcomitantATMMutations Identified by Next Generation Sequencing in a Patient With New-Onset Acute Myeloid Leukemia Following Imatinib Treatment for Chronic Myeloid Leukemia.

Stein MK, Crawley M, Vick E, Martin MG.

World J Oncol. 2018 Apr;9(2):66-67. doi: 10.14740/wjon1094w. Epub 2018 May 1. No abstract available. PMID: 29760836

 

  1. Recurrent Cytogenetic Abnormalities in Intravascular Large B-Cell Lymphoma.

Klairmont MM, Cheng J, Martin MG, Gradowski JF.

Am J Clin Pathol. 2018 May 14. doi: 10.1093/ajcp/aqy023. [Epub ahead of print] PMID: 29767679

 

  1. Desmoplastic small round cell tumor: A nationwide study of a rare sarcoma.

Stiles ZE, Dickson PV, Glazer ES, Murphy AJ, Davidoff AM, Behrman SW, Bishop MW, Martin MG, Deneve JL.

J Surg Oncol. 2018 Jun 7. doi: 10.1002/jso.25071. [Epub ahead of print] PMID:29878371

 

  1. Age-Related Chromosomal Aberrations in Patients with Diffuse Large B-Cell Lymphoma: AnIn Silico Approach.

Vick EJ, Richardson N, Patel K, Ramos GMD, Altahan A, Alloway T, Martin MG.

World J Oncol. 2018 Aug;9(4):97-103. doi: 10.14740/wjon1136w. Epub 2018 Sep 6. PMID: 30220946

 

  1. JAK Pseudokinase Domain Variants Highlight nRTK VUSs Identified with Next-Generation Sequencing in Solid Tumor Patients.

Stein MK, Morris LK, Martin MG.

Pathol Oncol Res. 2018 Jun 3. doi: 10.1007/s12253-018-0443-3. [Epub ahead of print] No abstract available. PMID:29862471

 

  1. A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.

Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin MG, Reynolds CH, Shain K, Zackon I, Stampleman L, Henrick P, Rivotto BJ, Hornburg K, Dumke H, Chuma S, Savell A, Handisides D, Kroll S, Anderson KC, Richardson PG, Ghobrial IM.

Clin Cancer Res. 2018 Oct 2. pii: clincanres.1325.2018. doi: 10.1158/1078-0432.CCR-18-1325. [Epub ahead of print] PMID: 30279233

 

Current Committee, teaching positions and offices held:

  1. National Comprehensive Cancer Network (NCCN) guidelines committee on Acute Myeloid Leukemia (2012 – present).
  2. Site Director University of Tennessee Hematology and Oncology Fellowship, Methodist University Hospital (October 2012 – present)
  3. Faculty Advisor University of Tennessee Medical Student Hematology and Oncology Interest Group (March 2013 – present), supported by an ASCO grant (2016-19).
  4. American Society of Clinical Oncology (ASCO) International Development and Education Award (IDEA) Mentor (Dr Adriana Hepner, Brazil) (2018)

 

Past Committees, teaching positions and offices held:

  1. Chair of Hematology Research Committee at the Accelerated Community Oncology Research Network (ACORN)

(January 2010 – March 2012).

  1. Elected Division representative for Hematology and Oncology Baptist Hospital Memphis (January 2011-December 2012).
  2. National Comprehensive Cancer Network (NCCN) guidelines committee on Colon, Rectal and Anal cancers (2012)
  3. Co-Chair Methodist University Hospital/University of Tennessee Joint Medical Oncology and Surgical Oncology conference (2013).
  4. Co-preceptor Methodist Oncology Pharmacy residency (September 2011 – June 2014).
  5. Lincoln Memorial University – DeBusk College of Osteopathic Medicine preceptor for Hematology and Oncology rotation (July 2012).
  6. Site principal investigator (West Clinic) and Executive Committee member of the Blood Cancer Research Program in conjunction with Dana Farber Cancer Institute (June 2013 – January 2016).
  7. Chair Methodist University Hospital Hematology and Oncology Morbidity and Mortality Conference (April 2013 – December 2015).
  8. Preceptor Christian Brothers University Physician Assistant program (July 2013 – June 2015).
  9. Preceptor University of Tennessee Physician Assistant program (April 2015 – December 2016).
  10. American Society of Clinical Oncology (ASCO) Annual Meeting reviewer (2017)
  11. National Comprehensive Cancer Network (NCCN) guidelines committee on B-Cell Lymphomas (2016 – 2017).
  12. National Comprehensive Cancer Network (NCCN) guidelines committee on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2016 – 2017).
  13. National Comprehensive Cancer Network (NCCN) guidelines committee on Hairy Cell Leukemia (2016 – 2017).
  14. National Comprehensive Cancer Network (NCCN) guidelines committee on T-Cell Lymphomas (2016 – 2017).
  15. National Comprehensive Cancer Network (NCCN) guidelines committee on Primary Cutaneous B-cell Lymphomas (2016 – 2017).

 

Conference Leadership:

  1. Scientific Committee member – West Cancer Center Second Annual Oncology Conference -http://www.westcancercenterconference.com/2016/#home-content (November 2016).
  2. Scientific Committee member – West Cancer Center Fourth Annual Oncology Conference -http://www.westcancercenterconference.com/2018/#home-content (November 2018).

 

Consulting:

(2007) Genzyme Oncology Clofarabine Advisory Board

(2008) Bayer Oncology Advisory Board

(2009) GSK Oncology Advisory Board

(2009) Lilly Oncology Advisory Board

(2009) Coronado Biosciences

(2017) Seattle Genetics Brentuximab Vedotin Advisory Board

 

Research and Other External Support:

Investigator Sponsored Trials:

  1. Vij R, Martin MG, et al. Non-myeloablative conditioning regimen for allogeneic transplantation with thymoglobulin, cytarabine, and clofarabine for myelodysplastic syndrome and acute myeloid leukemia. 11/07-6/08. Budget: $113,023; Funded by Genzyme. Results published in Bone Marrow Transplant. 2009; 44(1)13-7.

 

  1. Abboud CN, Martin MG, et al. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. Funded 3/08; Open 1/09. Budget: $236,270; Funded by Genzyme. Results published in Am J Hematol. 2014; 89(5):487-92. Jan 11. doi: 10.1002/ajh.23663.

 

Research Grants:

  1. Stein M, Wiedower E, Chandler JC, Martin MG. In Silico Analysis of Variants of Unknown Significance Identified by Next-Generation Sequencing to Predict Response to Platinum-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. West Cancer Center Research Award July 2016-June 2017: $10,000.

 

  1. Boles M, Lee C, Martin MG. Correlating Tau Protein in Blood with Brain Metastases in Lung Cancer Patients. 2017 West Cancer Center/University of Tennessee Health Science Center M1 Summer Cancer Research Program. September 2017: $4,000.

 

  1. Klairmont M, Martin MG, Gradowski J. The Genomic Landscape of Myeloid Sarcoma. 2018 University of Tennessee/West Cancer Center Trainee Award. September 2018.

 

Site Principle Investigator:

  1. A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients with Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma. SPONSOR: Allos Therapeutics, Inc. PROTOCOL NO: PDX-015 (Feb 2011 – April 2012).

 

  1. Phase 2 Study of Pemetrexed in Combination with Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. SPONSOR: Lilly PROTOCOL NO: H3E-MC-S132 (a) (September 2010 – Present).

 

  1. A phase II, multi-center, single arm, open label study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma SPONSOR: Novartis Pharmaceuticals Corporation PROTOCOL NO: CLBH589DUS71. (October 2010 – June 2011).

 

  1. A randomized, double-blind, placebo-controlled, multi-center phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy SPONSOR: Novartis Pharmaceuticals Corporation PROTOCOL NO: CRAD001N2301 (October 2010 – present).

 

  1. A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation. SPONSOR: Novartis Pharmaceuticals Corporation PROTOCOL NO: CTKI258A2204 (October 2010 – present).

 

  1. A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO). SPONSOR: Novartis Pharmaceuticals Corporation PROTOCOL NO: ICL670A2302 (October 2010 – present).

 

  1. Safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (December 2013 – present).

 

Invited Publications/Book Chapters:

  1. Picus J, Martin MG. Gastrointestinal Complications of Chemotherapy. The Chemotherapy Source Book, Michael C. Perry Ed. 4th edition. 2007:197-208.

 

  1. Martin MG, Welch J. The Leukemias. Washington Manual Hematology and Oncology Subspecialty Consult, 2nd edition, 2008.

 

  1. Welch J, Martin MG. The Myeloproliferative disorders. Washington Manual Hematology and Oncology Subspecialty Consult, 2nd edition, 2008.

 

  1. Martin MG. Melanoma. Washington Manual Hematology and Oncology Subspecialty Consult, 2nd edition, 2008.

 

  1. Martin MG, Vij R. Monographs on decitabine, thiotepa, thalidomide, lenalidomide and bortezomib. Essential Cancer Pharmacology: The Prescriber’s Guide. Cambridge University Press. Govindan R and S Maier, eds. 2009.

 

  1. Martin MG, Welch JS, Abboud CN. Novel therapies and molecular targets in acute lymphoblastic leukemia. Adult Acute Lymphocytic Leukemia. Humana, Advani A and HM Lazarus eds. 2009.

 

  1. Martin MG, Walter MJ, Graubert TA. Animal models of Myelodysplastic syndromes. In press.

 

  1. Prouet P, Riney J, Vick E, Wiedower E, Martin MG. Ibrutinib: Safety and Adverse Events. Advances in Medicine and Biology. Nova, 2017; volume 124; Berhardt LV ed.

 

Peer Reviewer:

Palliative Care: Research and Treatment (2008)

Clinical Lymphoma and Myeloma (2008)

Expert Opinion on Pharmacotherapy (2009)

Journal of the National Comprehensive Cancer Network (2012, 2016)

Clinical Breast Cancer (2017)

World Journal of Surgical Oncology (2017)

Evidence-Based Complementary and Alternative Medicine (2018)

Cancer Medicine (2018)

 

Published Abstracts:

 

  1. Martin MG, Grubaugh J. Examination of the possible leaking of leachate from the Shelby County Penal landfill into the Wolf River, Memphis, TN. Poster presentation at the 1998 National Conference on Undergraduate Research, Volume IV, p1240-4.

 

  1. Martin MG, Ardati A, Dunlay S. Case report: Small cell lung cancer presenting as a paraneoplastic syndrome characterized by recurrent episodic hypotension and bradycardia. Poster presentation at the 2006 North Carolina chapter of the American College of Physicians annual meeting.

 

  1. Martin MG, Currow DC, Abernethy AP. Predictors of fatigue and quality of life in a prospective palliative care cohort. Poster presentation at the 2006 ASCO Annual Conference. Abstract # 8571, p485s.

 

  1. Martin MG, Currow DC, Abernethy AP. Breadth of prescribing in palliative care, a prospective cohort study. Poster presentation at the 2006 annual Society of General Internal Medicine Conference. April 2006, Abstract # 156394, p69.

 

  1. Abernethy AP, Patwardhan MB, Herndon JE, Dowell J, Rowe KL, Martin MG, Zafar Y, and Morse M. Tracking performance: Can oncology practices respond to the new quality measures? Poster presentation at the ASCO GI Conference 2007, Abstr # 264.

 

  1. Zafar Y, Provenzale DT, Herndon JE, Dowell J, Patwardhan MB, Rowe KL, Martin MG, Morse M, and Abernethy AP. The impact of comorbidity on diagnosis and treatment of colorectal cancer (CRC). Poster presentation at the ASCO GI Conference 2007, Abstr # 261.

 

  1. Patwardhan M, Herndon JE, Rowe K, Martin MG, Zafar Y, Morse M, Abernethy AP. Can we accurately track colorectal cancer management using ASCO/NCCN quality measures? Poster Presentation at the Annual Meeting of the Duke Comprehensive Cancer Center. Durham, North Carolina. March 12, 2007. Abstract book page 174.

 

  1. Zafar Y, Provenzale D, Herndon JE, Dowell J, Patwardhan M, Rowe K, Martin MG, Morse M, Abernethy AP. The impact of comorbidity on diagnosis and treatment of colorectal cancer (CRC). Poster Presentation at the Annual Meeting of the Duke Comprehensive Cancer Center. Durham, North Carolina. March 12, 2007. Abstract book page 199.

 

  1. Rowe K, Patwardhan M, Herndon JE, Martin MG, Zafar Y, Morse M, Abernethy AP. Choice of adjuvant and first-line metastatic chemotherapy (CT) for colorectal cancer (CRC) treated in the Carolinas. Poster presentation at the 2007 ASCO Annual Conference. Abstract number 36147.

 

  1. Abernethy AP, Martin MG, Currow DC. Predictors of fatigue and quality of life in a prospective palliative care cohort. Poster presentation at the Multinational Association for Supportive Care in Cancer 2007 Symposium. St. Gallen, Switzerland. June 27-30, 2007. Supportive Care in Cancer 2007; In press. Abstract number pending.

 

  1. Martin MG, Wang-Gillam A, Atif A, Fong T, Gao F, Govindan R, Morgensztern D. Second-line systemic therapy for esophageal cancer. ASCO 2008; Abstract 15623.

 

  1. Martin MG, Uy G, Procknow E, Walter MJ, Graubert TA, Tomasson M, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R. Allogeneic stem cell transplantation conditioning for MDS and AML with clofarabine, cytarabine and ATG. ASH 2008; Abstract 4427.

 

  1. Martin MG, Welch JS, Augustin K, Hladnick L, Abboud CN. Cladribine in the treatment of acute myeloid leukemia. ASH 2008; Abstract 4032.

 

  1. Martin MG, Walgren R, Procknow E, Westervelt P, Abboud CN, Cashen AF, Uy G, Stockerl-Goldstein K, Gao F, DiPersio JF, R Vij. Azacitidine-induced changes in the MDS methylome are associated with clinical responses. ASH 2008; Poster presentation, Abstract 2691.

 

  1. SEER analysis of subcutaneous panniculitis-like T-cell lymphoma (SPTL).

Martin MG, Cashen AF.

J Clin Oncol. 2009 May 20;27(15_suppl):e19527.

PMID: 27960920

 

  1. Martin MG, Jacoby M, Deych E, Graubert TA, Walter MJ. BRCA1 and BRCA2 nucleotide variants in young women with therapy related acute myeloid leukemia. Washington University Hematopoiesis Development and Malignancy Program Retreat, Oral presentation, abstract 1.

 

  1. Kilannin K, Chen TH, Tibbitts J, Martin MG, Walter MJ. B-Cell Progenitors Are Reduced in Hspa9 haploinsufficient Mice. ASH 2011; Abstract 3829.

 

  1. Jacoby M, Martin MG, Reineck T, Westervelt P, DiPersio JF, Cashen A, Stockerl-Goldstein K, Uy GL, Vij R, Abboud CN. Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia. ASH 2011; Abstract 3633.

 

  1. Martin MG, Fryar B, Danesi H, Schwartzberg LS. Phase IB study of an all-oral chemotherapy regimen, tesetaxel plus capecitabine, in patients with advanced solid tumors. ASCO 2012; Abstract 3085.

 

  1. Vontela NR, Naini P, Shuman M, Martin MG. CLAG – A novel therapeutic option for secondary myelofibrosis, TN ACP; Nov 2012.

 

21. Martin TG, Panjabi S, Kerr J, Martin MG, Walker MS.  Association Of Treatment Induced Peripheral Neuropathy (TIPN) With Treatment Patterns and Outcomes In Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM)

ASH 2013; Abstract 1750.

 

  1. Martin TG, Panjabi S, Kerr J, Martin MG,Walker MS.  Association of Treatment Induced Peripheral Neuropathy with Treatment Patterns and Outcomes in Patients with Newly Diagnosed Multiple Myeloma. Poster presentation. Academy of Managed Care Pharmacy (AMCP) and The Journal of Managed Care Pharmacy (JMCP) 26th Annual Meeting & Expo in Tampa, Florida April 1-4, 2014.

 

  1. Jamy O, Yaghmour G, Hare F, Chandler JC, Stelts S, Azari L, Martin MG. SEER analysis of outcomes for primary small cell carcinoma of the ovary. ASCO 2014; Abstract e16512.

 

  1. Hare F, Patel JK, Fenton MJ, Martin MG. SEER analysis of outcomes for primary small cell carcinoma of the breast. ASCO 2014; Abstract e12040.

 

  1. Wiedower E, Chandler JC, Pallera AM, Johnson RA, Munene G, Dickson P, Deneve JL, Fleming MD, Tauer KW, Schwartzberg LS, Martin MG. Effect of rituximab on outcomes in gastric B-cell lymphomas and on early mortality in gastric DLBCL. ASCO 2014; Abstract e19501.

 

  1. Yaghmour G, Johnson BC, Lawson RD, Martin MG. Insurance and outcomes for classical Hodgkin lymphoma. ASCO 2014; Abstract e19505.

 

  1. Laubach JP, Raje N, Armand P, Schlossman RL, Rosenblatt J, Matous JV, Hedlund J, Martin MG, Reynolds C, Shain K, Zackon I, Stampleman L, Boswell EN, Chuma S, Handisides DR, Kroll S, Ghobrial IM, Anderson KC, Richardson PG. Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). ASCO 2014; Abstract 8534.

 

  1. Pandey M, Sutton GR, Portnoy DC, Tauer KW, Schwartzberg LS, Dickson P, Martin MG. Relationship of grade to prognosis in localized primary angiosarcoma of the breast (PAOB). ASCO 2014; Abstract 10559.

 

  1. Fintel A, Jamy O, Chandler JC, Martin MG. Social connectivity and outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). ASCO 2014; Abstract 7049.
  2. Laubach JP, Raje N, Armand P, Schlossman RL, Rosenblatt J, Matous JV, Hedlund J, Martin MG, Reynolds C, Shain K, Zackon I, Stampleman L, Boswell EN, Chuma S, Handisides DR, Kroll S, Ghobrial IM, Anderson KC, Richardson PG. Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). EHA 2014; Abstract P360.
  3. Wiedower E, Chandler JC, Martin MG. The addition of rituximab to chemotherapy increases early mortality in gastric DLBCL but not gastric MALTomas. ASH Lymphoma Biology Meeting 2014; poster number 103.

 

  1. Pandey M, Sutton GR, Portnoy DC, Tauer KW, Schwartzberg LS, Dickson P, Martin MG. Relationship of grade to prognosis in localized primary angiosarcoma of the breast (PAOB). Poster presentation 24th Annual Mayo Clinic Hematology/Oncology Reviews 2014.

 

  1. Hare F, Patel J, Fenton M, Martin MG. The effect of adjuvant radiation on survival for patients with resected localized or regional primary small cell carcinoma of the breast. ASCO 2014 Breast Cancer Symposium; Abstract 87.

 

  1. Yaghmour G, Hahn A, Martin MG. Age and Population-Based Early Mortality Rate (EMR) in Acute Myeloid Leukemia (AML) Versus the EMR Reported By SWOG. ASH Annual Meeting 2014; Abstract 3665.
  2. Giri S, Pathak R, Li B, Prouet P, Martin MG. Acute Megakaryocytic Leukemia (AMegL) is associated with inferior outcomes relative to other Acute Myeloid Leukemia (AML) morphologies. ASH Annual meeting 2014; Abstract 2285.

 

  1. Giri S, Pathak R, Aryal MR, Karmacharya P, Martin MG. Weekend versus weekday mortality for Thrombotic Thrombocytopenic Purpura (TTP) related hospitalizations in the United States: Data from the National Inpatient Sample. ASH Annual meeting 2014; Abstract 4863.

36. Laubach JP, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Matous JV, Hedlund J, Martin MG, Reynolds C, Shain K, Zackon I, Stampleman L, Boswell EN, Chuma S, Liguori R, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM. A Phase 1/2 Trial of TH-302 and Dexamethasone Without or With Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma. ASH Annual meeting 2014; Abstract 2142.

 

  1. Prouet P, Giri S, Pathak R, Li B, Martin MG. Acute megakaryocytic leukemia is associated with inferior outcomes relative to other acute myeloid leukemia (AML) morphologies. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Oral presentation, abstract 2.

 

  1. Giri S, Pathak R, Aryal MR, Karmacharya P, Martin MG. Weekend versus weekday mortality for Thrombotic Thrombocytopenic Purpura (TTP) related hospitalizations in the United States: Data from the National Inpatient Sample. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 34.

 

  1. Hahn A, Giri S, Yaghmour G, Martin MG. Early Mortality in Acute Myeloid Leukemia. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 38.

 

  1. Jamy O, Yaghmour G, Hare F, Martin MG. SEER analysis of outcomes for primary small cell carcinoma of the ovary. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 42.

 

  1. Pandey M, Portnoy DC, Tauer K, Schwartzberg L, Dickson P, Martin MG. Grade drives prognosis in localized primary angiosarcoma of the breast (PAOB). Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 57.

 

  1. Patel JK, Hare F, Fenton M, Martin MG. Adjuvant Radiation Does Not Improve Survival for Patients with Resected Localized or Regional Primary Small Cell Carcinoma of the Breast (SCCB). Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 59.

 

  1. Wiedower E, Chandler J, Martin MG. The addition of rituximab to chemotherapy increases early mortality in gastric DLBCL but not gastric MALTomas. Alpha Omega Alpha/University of Tennessee College of Medicine Research Day. Poster presentation, abstract 80.

 

  1. Hahn A, Giri S, Pathak R, Bhatt VR, Martin MG. The effect of adjuvant radiotherapy on survival in locoregional urothelial malignancies of the upper urinary tract. ASCO 2015 annual meeting abstract e15636.

 

  1. Pathak R, Giri S, Martin MG, Bhatt VR. Survival of BCR-ABL positive and negative chronic myeloid leukemia: A propensity matched analysis of the Surveillance, Epidemiology and End Results database. ASCO 2015 annual meeting abstract e18053.

 

  1. Giri S, Pathak R, Bhatt VR, Martin MG. Impact of hospital volume on outcomes of patients undergoing chemotherapy for Acute Myeloid Leukemia (AML): a matched cohort study. ASCO 2015 annual meeting abstract e18067.

 

  1. Franklin R, Giri S, Valasareddy P, Pathak R, Martin MG. A population based comparison of survival among patients with anal adenocarcinoma (AA), anal squamous cell carcinoma (ASCC), and rectal adenocarcinoma (RA). ASCO 2015 annual meeting abstract e14500.

 

  1. Porter J, Chi MT, Giri S, McCormick D, Martin MG. Prognosis and outcomes of adult secondary acute lymphoblastic leukemia (sALL). ASCO 2015 annual meeting abstract e18061.

 

  1. Wiedower E, Jamy OH, Martin MG. Induction of acute myeloid leukemia (AML) with Idarubicin, Cytarabine and Cladribine (ICC). ASCO 2015 annual meeting abstract e18048.

 

  1. Pathak R, Giri S, Martin MG, Bhatt VR. Survival of de novo and secondary acute promyelocytic leukemia: A propensity matched analysis of the Surveillance, Epidemiology and End Results database. ASCO 2015 annual meeting abstract xx, poster presentation.

51. Laubach  JP, Raje SR, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin MG, Reynolds C, Shain, KH, Zackon I, Stampleman L, Boswell EN, Chuma S,  Liguori R , Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM.  Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia activated prodrug combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM). ASCO 2015 Annual meeting poster presentation.

 

  1. Wiedower E, Giri S, Fintel A, Prouet P, Paulus E, Chandler JC, Martin MG. The addition of rituximab to chemotherapy decreased rates of primary surgery for gastric DLBCL without increasing early mortality. Poster Presentation ASH Hematologic Malignancy meeting abstract no 45. Poster presentation ASH Annual meeting abstract no 4475.
  2. Jamy O, Giri S, Wiedower E, Johnson B, Nunnery S, Chandler JC, Martin MG. Under-Recognition of Hemophagocytic Lymphohistiocytosis in United States Rural, Non-Teaching Hospitals. Poster presentation ASH Hematologic Malignancy meeting abstract no 44. Poster presentation ASH Annual meeting abstract no 2079.
  3. Giri S, Nunnery S, Naseer S, Martin MG. Outcome of adolescents and young adults with acute myeloid leukemia (AML) as compared to pediatric AML patients: Real world data from SEER registry. Poster presentation ASH Hematologic Malignancy meeting abstract no 18. Poster presentation ASH Annual meeting abstract no 4484.
  4. Johnson B, Giri S, Nunnery S, Wiedower E, Chander JC, Martin MG. Comorbidities Drive Outcomes for Both Malignancy and Non-Malignancy Associated Hemophagocytic syndrome. Poster presentation ASH Hematologic Malignancy meeting abstract no 71. . Poster presentation ASH Annual meeting abstract no 3261.
  5. Weatherall TJ, Denbo JW, Sharpe JP, Martin MG, Ismail M, O’Brien T, Groshart K, Gupta R, Behrman SW, Deneve JL, Munene G, Dickson PV. Treatment of Non-Functional, Non-Ampullary Duodenal Neuroendocrine Tumors. Oral presentation 11th Annual Academic Surgical Congress, February 2-4, 2016 in Jacksonville, FL.

 

  1. Michael P Thompson, Teresa M Waters, Erin Kaplan, Caitlin N McKillop, Martin MG. Hospital volume and post-discharge mortality in Medicare beneficiaries aged 65 and older with acute leukemia. Poster presentation at the ASCO 2016 Annual Meeting abstract no. 6560.

 

  1. Michael P Thompson, Teresa M Waters, Erin Kaplan, Caitlin N McKillop, Martin MG. The volume-outcome relationship in emergent vs. non-emergent admissions for acute leukemia in Medicare beneficiaries aged 65 and older, ASCO 2016 Annual Meeting abstract no. e18109.

 

  1. Teresa M Waters, Michael P Thompson, Erin Kaplan, Caitlin N McKillop, Martin MG. The volume-outcome relationship in Medicare beneficiaries aged 65 and older with acute myeloid leukemia and acute lymphocytic leukemia, ASCO 2016 Annual Meeting abstract no. e18110.

 

  1. Catherine Gorman Ireland, Muhammad Mudassir Mirza, Alexandria Tran, Jason Claud Chandler, Monika Metzger, Martin MG. Impact of provider volume on outcomes of patients with Hodgkin lymphoma, ASCO Annual Meeting abstract no. e18203.

 

  1. George Yaghmour, Omer HASSAN Jamy, Philippe Prouet, Manjari Pandey, Martin MG. Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO), ASCO 2016 Annual Meeting abstract no. e17053.

 

  1. Brennan McCullar, Manjari Pandey, Felicia Hare, Kruti Patel, Matthew Stein, Melissa Crawley, George Yaghmour, Rebecca Feldman, Martin MG. Genomic landscape of small cell carcinoma of the breast (SCCB) contrasted to small cell carcinoma of the lung (SCLC), ASCO 2016 Annual Meeting abstract no. e23281.

 

  1. George Yaghmour, Manjari Pandey, Catherine Gorman Ireland, Kruti Patel, Sarah Elizabeth Nunnery, Daniel Powell, Scott Baum, Eric Wiedower, Lee Steven Schwartzberg, Martin MG. Role of genomic instability in immunotherapy with checkpoint inhibitors. Poster presentation at the ASCO Annual Meeting abstract no. 3052.

 

  1. Syed Sameer Nasir, Smith Giri, Sarah Elizabeth Nunnery, Eric Wiedower, Martin MG. Outcomes of adolescents and young adults (AYAs) compared to pediatric patients with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL): Real world data from the SEER registry, ASCO 2016 Annual Meeting abstract no. e18506.

 

  1. Mirza M, McCullar B, Martin MG. Therapy related Myeloid and Lymphoid Neoplasms in BRCA mutated Breast and Ovarian Cancer patients. ASH Hematologic Malignancies 2016 Poster Abstract 10; ASH Annual Meeting 2016 abstract 5115.

 

  1. Vontela NR, Byrd K, McCullar B, Martin MG. Multi-Database Description of Primary Splenic Diffuse Large B-cell Lymphoma. ASH Hematologic Malignancies 2016 Poster abstract 39; ASH Annual Meeting 2016 abstract 5399.

 

  1. Patel D, Riney J, Hahn A, Stein M, Martin MG. Distribution of 9p24 Abnormalities in Hematologic Malignancies with an Emphasis on Diffuse Large B-cell lymphoma. ASH Hematologic Malignancies 2016 Poster abstract 40; ASH Annual Meeting 2016 Poster abstract 1866.

 

  1. Patel K, Lee SS, Valasareddy P, Vontela N, Martin MG. Genetic Analysis of B-cell Lymphomas Associated with Hemaphagocytic Lymphohistiocytosis. ASH Hematologic Malignancies 2016 Poster abstract 42; ASH Annual Meeting 2016 abstract 5315.

 

  1. Crawley MA, Stein M, Patel K, Martin MG. Clinical Trial Availability in Adolescent and Young Adult Patients with Non-Hodgkin Lymphoma. ASH Hematologic Malignancies 2016 Poster abstract 44; ASH Annual Meeting 2016 abstract 5937.

 

  1. Stein M, Riney J, Patel D, Hahn A, Martin MG. Increased Prevalence of t(8;9)(p21-23;p23-24) Translocations within 9p24 Abnormalities in Patients with Myeloid Malignancies Identified from the Mitelman database. ASH Hematologic Malignancies 2016 Poster abstract 67; ASH Annual Meeting 2016 Poster abstract 1935.

 

  1. Giri U, Martin MG. Survival Outcomes in Grade 3 Follicular Lymphoma Prior to and after the Introduction of Rituximab – an Analysis Based on the Surveillance, Epidemiology, and End Result Registry Database. ASH Annual Meeting 2016; Poster abstract 2967.

 

  1. Laubach JP, Raje NS, Yee AJ, Amand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin MG, Reynelds C, Shain KH, Zackon I, Stampleman L, Lai E, Cada A, Rivotto B, Reyes K, Savell A, Henrick P, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM. Final results of the Phase I/II Open-label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Evofosfamide, A Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. ASH Annual Meeting 2016 Poster abstract.

 

  1. Juan Carlos Malpartida, Eric Vick, Noah Hunter Richardson, Kruti Patel, Matthew K Stein, Martin MG. Distribution of ETV6-NTRK3 translocations across neoplasms identified from the Mitelman Database. 2017 Annual Meeting Abstract No. e23141. J Clin Oncol 35, 2017 (suppl; abstr e23141)

 

  1. Lindsay Kaye Morris, Alaa Altahan, John Mays, Upama Giri, Eric Wiedower, Daniel A. Vaena, Martin D. Fleming, Martin MG. Impact of Margin Status on Survival after Radical Nephrectomy for Renal Cell Carcinoma (RCC). ASCO 2017 Annual Meeting Abstract No. e16084. J Clin Oncol 35, 2017 (suppl; abstr e16084)

 

  1. Ari M. Vanderwalde, Matthew K Stein, Lindsay Kaye Morris, Srishti Sareen, Saradasri Karri, Kruti Patel, Jennifer Sullivan, Lee Steven Schwartzberg, Martin MG. Distribution and pathogenicity of nsSNPs in receptor tyrosine kinases (RTKs) in non-small cell lung cancer (NSCLC) patients (pts). 2017 ASCO Annual Meeting Abstract No. e20618. J Clin Oncol 35, 2017 (suppl; abstr e20618)

 

  1. Matthew K Stein, Lindsay Kaye Morris, Jennifer Sullivan, Moon Jung Fenton, Ari M. Vanderwalde, Lee Steven Schwartzberg, Martin MG. Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain (TKD) with next-generation sequencing (NGS). 2017 ASCO Annual Meeting Abstract No. e20506.

J Clin Oncol 35, 2017 (suppl; abstr e20506)

 

  1. Matthew K Stein, Saradasri Karri, Lindsay Kaye Morris, Srishti Sareen, Kruti Patel, Ray Scott Daugherty, David Shibata, Ari M. Vanderwalde, Lee Steven Schwartzberg, Martin MG. Distribution and pathogenicity of nsSNPs in receptor tyrosine kinases (RTKs) in patients with colorectal cancer. 2017 ASCO Annual Meeting Abstract No. e15012. J Clin Oncol 35, 2017 (suppl; abstr e15012).

 

  1. Lindsay Kaye Morris, Matthew Stein, Saradasri Karri, Srishti Sareen, Kruti Patel, Gregory A. Vidal, Lee Steven Schwartzberg, Martin MG. Distribution of receptor tyrosine kinase (RTK) nsSNPs in breast cancer (BC) patients (pts) using next-generation sequencing (NGS). 2017 ASCO Annual Meeting Abstract No. 1080.

J Clin Oncol 35, 2017 (suppl; abstr 1080)

 

  1. Saradasri Karri, Matthew K Stein, Kruti Patel, Melissa Crawley, Namratha Reddy Vontela, Taylor Alloway, Lindsay Kaye Morris, John Mays, Felicia Hare, Philippe Prouet, Kenneth P Byrd, Eric Wiedower, Jason Claud Chandler, Moon Jung Fenton, Benny Weksler, Lee Steven Schwartzberg, Martin MG. In silico analysis of DNA damage repair variants in advanced NSCLC patients (pts) to predict response to platinum-based chemotherapy (PBC). 2017 ASCO Annual Meeting Abstract No. e20582. J Clin Oncol 35, 2017 (suppl; abstr e20582)

 

  1. Srishti Sareen, Matthew Stein, Lindsay Kaye Morris, Saradasri Karri, Kruti Patel, David Shibata, Ari M. Vanderwalde, Lee Steven Schwartzberg, Martin MG. Localization of non-receptor tyrosine kinase (nRTK) variants in solid tumor patients using next-generation sequencing (NGS). 2017 ASCO Annual Meeting Abstract No. 1536; Poster Session (Board #194). J Clin Oncol 35, 2017 (suppl; abstr 1536)

 

  1. Kruti Patel, Matthew K Stein, Lindsay Kaye Morris, Kenneth P Byrd, Benny Weksler, Lee Steven Schwartzberg, Moon Jung Fenton, Ari M. Vanderwalde, Martin MG. In silico analysis of non-synonymous SNPs (nsSNPs) and outcomes in non-small cell lung cancer (NSCLC) patients (pts) treated with immunotherapy (IT). 2017 ASCO Annual Meeting Abstract No. e14563. J Clin Oncol 35, 2017 (suppl; abstr e14563)

 

  1. Upama Giri, Eric Vick, Sophia SeoHyeon Lee, Alaa Altahan, Noam Avraham VanderWalde, Paxton Vandiver Dickson, Jeremiah Lee Deneve, Martin MG. Survival outcomes for various treatment modalities in early-stage grade 3 follicular lymphoma (FL3): a National Cancer Database (NCDB) study. 2017 ASCO Annual Meeting Abstract No. 7551. Poster Session (Board #313). J Clin Oncol 35, 2017 (suppl; abstr 7551)

 

  1. Upama Giri, Eric Vick, Sophia SeoHyeon Lee, Alaa Altahan, Noam Avraham VanderWalde, Paxton Vandiver Dickson, Jeremiah Lee Deneve, Martin MG. Survival outcomes for various treatment modalities in advanced-stage grade 3 follicular lymphoma (FL3): A National Cancer Database (NCDB) study. ). 2017 ASCO Annual Meeting Abstract No. 7554. Poster Session (Board #316). J Clin Oncol 35, 2017 (suppl; abstr 7554)

 

  1. Alaa Altahan, Eric Vick, Upama Giri, Eric Wiedower, Martin MG. Effect of adding immunotherapy (IT) to treatment regimen of mantle cell lymphoma (MCL): Analysis of the National Cancer Data Base (NCDB). 2017 ASCO Annual Meeting Abstract No. e19022. J Clin Oncol 35, 2017 (suppl; abstr e19022)

 

  1. Stein MK,Morris LK, Martin MG. JAK Pseudokinase Domain Variants Highlight nRTK nsSNPs Identified with Next-Generation Sequencing in NSCLC Patients (Oral presentation). 18th World Conference on Lung Cancer (2017)

Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan. MA 06.07

 

86. Vick E, Patel K, Richardson N, Alloway T, Delgado Ramos GM, Altahan A, Martin MG. Age-Related Chromosomal Aberrations in Patients with Diffuse Large B-Cell Lymphoma. ASH 2017 abstract 1571 (poster)

  1. Khaled Y, Chandler JCC, Boss J, Pallera A, Martin MG, Bradley R, Johnson R. T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates. ASH 2017 abstract 1934 (poster).

 

  1. Giri U, Patel K, Martin MG. Second Primary Malignancies and Cardiovascular Mortality in Hodgkin disease Survivors – a Surveillance, Epidemiology, and End Results Registry Database Study. ASH 2017 abstract 1513 (poster).

 

  1. Byrd K, Hayes T, Martin MG, Schwartzberg L, VanderWalde A. Clinical outcomes of PD-1 inhibition by PD-L1 expression levels across malignancies in 204 consecutive patients in a real world oncology setting [abstract]. In: SITC 32nd Annual Meeting; November 8-12, 2017; National Harbor, MD: Abstract 311.

 

  1. Stiles ZE, Dickson PV, Glazer ES, Murphy AJ, Davidoff AM, Behrman SW, Bishop MW, Martin MG, Deneve JL. Desmoplastic Small Round Cell Tumor: A Nationwide Study of a Rare Sarcoma. Society of Surgical Oncology 2018 Abstract 110.

 

  1. Porter J, Boles M, Pandey M, Prouet P, Hare F, Nasir SS, Zetterberg H, Martin MG. Measuring serum neurofilament light (sNfL) levels to determine correlation with activity of brain metastases (BM) and gliomas (G). ASCO 2018 Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr e24028

 

  1. Stein MK, Martin MG, Xiu J, Mittal S, Phuphanich S, Provenzano AP, Michelhaugh S, Brenner AJ, Subramaniam DS, Sumrall AL, Heimberger AB, Kesari S, Korn WM, Pandey MK. Mutational complexity increases in lung adenocarcinoma (LADC) with the development of brain metastasis (BM). J Clin Oncol 36, 2018 (suppl; abstr 2067)

 

  1. Altahan A, Martin MG. Association between pesticides use and incidence of diffuse large B cell lymphoma (DLBCL). J Clin Oncol 36, 2018 (suppl; abstr 1570)

Medical Mission Work:

  1. Worked as a translator on a weeklong medical mission to rural Monterey, Mexico (August 1999).
  2. Organized and lead a medical mission to Nicaragua with 6 doctors and over 10 nurses and aides in conjunction with Three Fold Ministries (September 2011).

 

Media appearance:

  1. TV Appearance on Arise News, Lagos, Nigeria https://youtu.be/0fBg6nwMhnU

 

Other publications:

  1. Writer for Smartest Oncologist in America (www.thesmartestoncologist.com), August 2007 – August 2012.
  2. Martin MG. Monographs on Sources of stem cells, Target CD34 dose, Engraftment, Prognostic scoring and staging, and SOS/VOD in the Washington University Guide to Bone Marrow Transplantation (2008).

 

Past Clinic Fellows:

Dr. Eric Wiedower (2014 – 2016) – Assistant Professor of Medicine, The University of Tennessee

Dr. Kenneth Byrd (2016 – 2018) – Assistant Professor of Medicine, The University of Kansas

Dr. Phil Prouet (2017 – current)

Dr. Matthew K. Stein (2018 – current)